Related Experiment Video

Updated: May 16, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin

Ho Young Kim1, Sung Keun Jung, Sanguine Byun

  • 1WCU Major in Biomodulation, Department of Agricultural Biotechnology, Seoul National University, Seoul, 151-921, Republic of Korea; Department of Agricultural Biotechnology, Seoul National University, Seoul, 151-921, Republic of Korea.

Phytotherapy Research : PTR
|November 23, 2012
PubMed

Insights

Luteolin, a natural compound, effectively inhibited cancer metastasis in mice by targeting key signaling pathways. This phytochemical shows promise as a novel anti-metastatic agent for cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Metastasis is the leading cause of cancer mortality.
  • Luteolin, a phytochemical, exhibits anticancer properties in vitro.
  • The in vivo anti-metastatic effects and mechanisms of luteolin are not well understood.

Purpose of the Study:

  • To investigate the anti-metastatic effects of luteolin in vivo.
  • To elucidate the molecular mechanisms underlying luteolin's anti-metastatic action.
  • To identify potential molecular targets of luteolin in cancer metastasis.

Main Methods:

  • In vitro assays using murine colorectal cancer CT-26 cells to assess MMP-2 and MMP-9 activity and invasion.
  • Western blot and kinase assays to evaluate Raf, PI3K, MEK, and Akt signaling.
  • In vivo mouse model of lung metastasis induced by CT-26 cells.
  • Oral administration of luteolin in mice.

Main Results:

  • Luteolin suppressed MMP-2 and MMP-9 activities and invasion in CT-26 cells.
  • Luteolin inhibited Raf and PI3K activities, leading to decreased MEK and Akt phosphorylation.
  • Luteolin non-competitively bound ATP to inhibit Raf and competitively bound ATP to inhibit PI3K.
  • In vivo, luteolin administration significantly reduced lung metastasis nodules and tumor volume.
  • Luteolin inhibited MMP-9 expression and activity in mouse lung tissue.

Conclusions:

  • Luteolin demonstrates significant in vivo anti-metastatic potential against colorectal cancer lung metastasis.
  • The anti-metastatic effects of luteolin are mediated through the inhibition of Raf/MEK and PI3K/Akt signaling pathways.
  • Luteolin warrants further investigation as a potential therapeutic agent for preventing cancer metastasis.
Keywords:
MMP-2/9PI3KRaf kinaselung metastasisluteolin

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...